International Cardio events

More information>>>

20 International congress of updates in cardiology 6-9 June 2024, Istanbul, Turkey More information at >>>

More information>>>

INTERNATIONAL HEART CONGRESS 2023 23-25 May, Tokyo, Japan More information at >>>

The 33rd Great Wall International Cardiology Conference 28-30 October 2022, Beijing, China More information at >>>

CBC TOGETHER WITH WCC 2022 13-15 October 2022, Rio de Janeiro, Brazil More information at >>>

Intense Septal Enhancement on Cardiac MRI Flags Cardiac Amyloidosis A retrospective study showed that intensive gadolinium contrast enhancement of the anterior interatrial septum during cardiac magnetic resonance imaging, with a high degree of specificity (98%), makes it possible to diagnose cardiac amyloidosis when compared with hypertrophic cardiomyopathy and dilated cardiomyopathy.

Weight Loss During Heart Failure Hospitalization Linked to Lower 30-Day Rehospitalization Risk Patients hospitalized for heart failure who were treated with intravenous loop diuretics and achieved a weight loss of at least 2 kg between admission and discharge had a reduced risk for HF rehospitalization within 30 days.

Allergic vasospastic angina: a systematic review Allergic vasospastic angina (also known as Kunis syndrome) is a little‑studied subtype of vasospastic angina in which spasm of the coronary arteries is triggered by an allergen. Scientists conducted a study in which they assessed the clinical characteristics, mechanisms, and treatment methods for this interesting subtype of angina.

Fitness Changes Over Time Linked to Cardiovascular Risk A large UK Biobank analysis showed that even a small annual improvement in cardiorespiratory fitness among adults was independently associated with lower risks for incident cardiovascular disease and cardiovascular mortality, whereas declining fitness was linked to a progressively higher risk in a clear dose-dependent pattern.

Cardioprotection Rarely Used in Adults With Blood Cancers In a US cohort study of adults on anthracycline-based therapy for hematologic cancers, only 1%-2% received strategies to lower the risk for treatment-related heart damage.

CARDIOPROGRESS
Foundation for the advancement of cardiology